Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation

Author(s): Anlun Ma, Huifang Chen

Journal Name: Current Drug Targets - Cardiovascular & Hematological Disorders
Continued as Cardiovascular & Hematological Disorders-Drug Targets

Volume 2 , Issue 2 , 2002


Immunosuppression is currently the major approach used for the prevention and management of transplant rejection. In this overview, preclinical and clinical studies of the small molecule immunosuppressive agents are reviewed from the discovery of cyclosporine. More recently it was demonstrated that certain agents, namely tacrolimus (FK506), sirolimus (rapamycin), and mycophenolate mofetil (CellCept, MMF), act selectively on adaptive host responses at different stages of T- and B-cell cycles and spare nonspecific host resistance. Because each agent has its specific and significant toxic effects, it has been difficult to optimize the use of individual agents in monotherapy. Therefore, drug combination therapy has been of great interest in addition to the introduction of new small molecule agents, such as malononitrilamides [MNAs (leflunomide, FK778, FK779)], 15-deoxyspergualin (DSG) and its analogues, FTY720 and inhibitors of signal transduction, which offer promising modes of immunosuppression.

Keywords: transplantation, immunosuppression, cyclosporine, tacrolimus, sirolimus, malononitrilamides, leflunomides, fty720, tepoxalin, sp100030

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [57 - 71]
Pages: 15
DOI: 10.2174/1568006023337466
Price: $65

Article Metrics

PDF: 2